The global pre-filled syringe (PFS) market is experiencing a period of substantial growth and is projected to almost double in value by 2030. This acceleration is driven by evolving healthcare requirements (i.e. an increasing demand for patient centricity and self-administration) and advancements in drug delivery (i.e. growth in biologics/biosimilars and improved syringe technology). PFS manufacturing is complex, from managing sensitive formulations including efforts to minimize high-value product loss to helping ensure precision in fill-finish operations and maintaining compliance with evolving regulatory standards.
In this white paper from Pfizer CentreOne, explore practical strategies and established methods designed to help address this complexity and support the reliable, scalable production of high-quality PFS therapies.